Shots:
The CHMP has recommended approval of an indication extension for Johnson & Johnson’s Talvey (talquetamab) + daratumumab ± pomalidomide for adults with relapsed/refractory multiple myeloma (RRMM) who have received ≥1 prior therapy; if approved, it will be the only GPRC5D-targeting bispecific antibody combination for RRMM as early as 2L
Recommendation was based on the…
